stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) EBITDA
Axsome Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$156.4M, compared with −$270.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$139.8M. Over the past ten years it has ranged from −$270.0M (fiscal 2024) to −$9.1M (fiscal 2015); the current reading is higher than 36% of that period. Axsome Therapeutics, Inc. ranks 460th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$156.4M | — |
| FY2024 | −$270.0M | — |
| FY2023 | −$222.4M | — |
| FY2022 | −$173.9M | — |
| FY2021 | −$123.6M | — |
| FY2020 | −$98.3M | — |
| FY2019 | −$66.6M | — |
| FY2018 | −$32.4M | — |
| FY2017 | −$26.7M | — |
| FY2016 | −$27.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$7.8M | — |
| Jun 2026 | −$46.6M | — |
| Mar 2026 | −$60.8M | — |
| Dec 2025 | −$24.5M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| AXSM Axsome Therapeutics, Inc. | −$139.8M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$186.2M |
| ABVX Abivax SA Sponsored ADR compare | −$338.0M |
| PRAX Praxis Precision Medicines, Inc. compare | −$380.8M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AXSM
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement